337 related articles for article (PubMed ID: 21514199)
1. The role of brachytherapy in the definitive management of prostate cancer.
Crook J
Cancer Radiother; 2011 Jun; 15(3):230-7. PubMed ID: 21514199
[TBL] [Abstract][Full Text] [Related]
2. Brachytherapy for clinically localized prostate cancer: optimal patient selection.
Kollmeier MA; Zelefsky MJ
Arch Esp Urol; 2011 Oct; 64(8):847-57. PubMed ID: 22052766
[TBL] [Abstract][Full Text] [Related]
3. [Prostate cancer brachytherapy].
Pommier P; Guérif S; Peiffert D; Créhange G; Hannoun-Lévi JM; de Crevoisier R
Cancer Radiother; 2016 Sep; 20 Suppl():S210-5. PubMed ID: 27523412
[TBL] [Abstract][Full Text] [Related]
4. Isotope selection for permanent prostate implants? An evaluation of 103Pd versus 125I based on radiobiological effectiveness and dosimetry.
Dicker AP; Lin CC; Leeper DB; Waterman FM
Semin Urol Oncol; 2000 May; 18(2):152-9. PubMed ID: 10875458
[TBL] [Abstract][Full Text] [Related]
5. Long-term results of an RTOG Phase II trial (00-19) of external-beam radiation therapy combined with permanent source brachytherapy for intermediate-risk clinically localized adenocarcinoma of the prostate.
Lawton CA; Yan Y; Lee WR; Gillin M; Firat S; Baikadi M; Crook J; Kuettel M; Morton G; Sandler H
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):e795-801. PubMed ID: 22330999
[TBL] [Abstract][Full Text] [Related]
6. Prostate specific antigen findings and biopsy results following interactive ultrasound guided transperineal brachytherapy for early stage prostate carcinoma.
Stock RG; Stone NN; DeWyngaert JK; Lavagnini P; Unger PD
Cancer; 1996 Jun; 77(11):2386-92. PubMed ID: 8635111
[TBL] [Abstract][Full Text] [Related]
7. The current role of imaging for prostate brachytherapy.
Carey B; Swift S
Cancer Imaging; 2007 Feb; 7(1):27-33. PubMed ID: 17339141
[TBL] [Abstract][Full Text] [Related]
8. [High dose rate prostate brachytherapy].
Nickers P; Blanchard P; Hannoun-Lévi JM; Bossi A; Chapet O; Guérif S
Cancer Radiother; 2013 Apr; 17(2):118-24. PubMed ID: 23578898
[TBL] [Abstract][Full Text] [Related]
9. [Permanent implant prostate cancer brachytherapy: 2013 state-of-the art].
Cosset JM; Hannoun-Lévi JM; Peiffert D; Delannes M; Pommier P; Pierrat N; Nickers P; Thomas L; Chauveinc L
Cancer Radiother; 2013 Apr; 17(2):111-7. PubMed ID: 23478488
[TBL] [Abstract][Full Text] [Related]
10. [Evolution of prostate cancer brachytherapy].
Hannoun-Levi JM; Chevallier D; Cosset JM; Gerbaulet A
Bull Cancer; 2012 Dec; 99(12):1175-81. PubMed ID: 23228827
[TBL] [Abstract][Full Text] [Related]
11. Intensity-modulated radiotherapy causes fewer side effects than three-dimensional conformal radiotherapy when used in combination with brachytherapy for the treatment of prostate cancer.
Forsythe K; Blacksburg S; Stone N; Stock RG
Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):630-5. PubMed ID: 22099032
[TBL] [Abstract][Full Text] [Related]
12. Evolution of techniques for ultrasound-guided palladium 103 brachytherapy in 950 patients with prostate cancer.
Sharkey J; Chovnick SD; Behar RJ; Perez R; Otheguy J; Rabinowitz R; Solc Z; Huff W; Cantor A; Steele J; Webster C; Donohue M
Tech Urol; 2000 Jun; 6(2):128-34. PubMed ID: 10798814
[TBL] [Abstract][Full Text] [Related]
13. There is a wide range of predictive dosimetric factors for I-125 and pd-103 prostate brachytherapy.
Herstein A; Wallner K; Merrick G; Orio P; Thornton K; Butler W; Sutlief S
Am J Clin Oncol; 2008 Feb; 31(1):6-10. PubMed ID: 18376221
[TBL] [Abstract][Full Text] [Related]
14. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
15. Combination external beam radiation and brachytherapy boost with androgen suppression for treatment of intermediate-risk prostate cancer: an initial report of CALGB 99809.
Hurwitz MD; Halabi S; Ou SS; McGinnis LS; Keuttel MR; Dibiase SJ; Small EJ
Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):814-9. PubMed ID: 18407435
[TBL] [Abstract][Full Text] [Related]
16. [Which modality for prostate brachytherapy?].
Bossi A
Cancer Radiother; 2010 Oct; 14(6-7):488-92. PubMed ID: 20724190
[TBL] [Abstract][Full Text] [Related]
17. Radiation safety of receptive anal intercourse with prostate cancer patients treated with low-dose-rate brachytherapy.
Nasser NJ; Cohen GN; Dauer LT; Zelefsky MJ
Brachytherapy; 2016; 15(4):420-425. PubMed ID: 27180125
[TBL] [Abstract][Full Text] [Related]
18. Twelve-month prostate-specific antigen values and perineural invasion as strong independent prognostic variables of long-term biochemical outcome after prostate seed brachytherapy.
Ding W; Lee J; Chamberlain D; Cunningham J; Yang L; Tay J
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(4):962-7. PubMed ID: 22494584
[TBL] [Abstract][Full Text] [Related]
19. American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer.
Nag S; Beyer D; Friedland J; Grimm P; Nath R
Int J Radiat Oncol Biol Phys; 1999 Jul; 44(4):789-99. PubMed ID: 10386635
[TBL] [Abstract][Full Text] [Related]
20. Biochemical disease-free survival rates following definitive low-dose-rate prostate brachytherapy with dose escalation to biologic target volumes identified with SPECT/CT capromab pendetide.
Ellis RJ; Zhou H; Kim EY; Fu P; Kaminsky DA; Sodee B; Colussi V; Vance WZ; Spirnak JP; Kim C; Resnick MI
Brachytherapy; 2007; 6(1):16-25. PubMed ID: 17284381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
